HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA rebuts study

This article was originally published in The Tan Sheet

Executive Summary

The American Herbal Products Association says April 25 a case report concluding a kelp supplement caused arsenic poisoning is inaccurate. The April issue of Environmental Health Perspectives links kelp to a woman with worsening hair loss, memory loss and fatigue (1"The Tan Sheet" April 16, 2007, p. 3). AHPA says the woman ignored a specific label caution and iodine overdose, not arsenic poisoning, may have been an explanation for the woman's symptoms. "The authors fail to report that the product was used at two- to 'at least' four-times the suggested amount, of potential significance due to the naturally occurring presence of iodine in kelp," AHPA says...

You may also be interested in...



ARC Association Forms To Help Industry Address Standards, Testing

A group of scientific experts have united to "meet the common needs and aspirations of the dietary supplement industry in the area of analytical science," the newly formed Analytical Research Collective announces April 13

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel